Ticker: TCRX

TScan Therapeutics, Inc. (NYSE: TCRX) - Quick read on what's happening inside Short summary: the company is stepping up R&D and converting collaboration activity (Amgen) into recognitions of revenue while continuing to burn cash. Management says current resources fund operations into Q1 2027, but...

TScan Therapeutics, Inc. (NYSE: TCRX) continues to navigate a challenging landscape as a biotechnology company focused on developing innovative T cell receptor (TCR)-engineered therapies for cancer treatment. Recent developments reflect both promising advancements and significant financial hurdle...